-
1
-
-
0028966356
-
Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival
-
Rasmussen A, Davies HF, Jamieson NV, et al. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. Transplantation 1995;59:919-21.
-
(1995)
Transplantation
, vol.59
, pp. 919-921
-
-
Rasmussen, A.1
Davies, H.F.2
Jamieson, N.V.3
-
2
-
-
33747489301
-
Combined lung and liver transplantation: The United States experience
-
Kotru A, Sheperd R, Nadler M, et al. Combined lung and liver transplantation: the United States experience. Transplantation 2006;82:144-5.
-
(2006)
Transplantation
, vol.82
, pp. 144-145
-
-
Kotru, A.1
Sheperd, R.2
Nadler, M.3
-
3
-
-
0019796723
-
Reversal of transplantation immunity by liver grafting
-
Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981;292:840-3.
-
(1981)
Nature
, vol.292
, pp. 840-843
-
-
Kamada, N.1
Davies, H.S.2
Roser, B.3
-
4
-
-
33645554690
-
The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: An analysis of the OPTN database
-
Navarro V, Herrine S, Katopes C, et al. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl 2006;12:652-8.
-
(2006)
Liver Transpl
, vol.12
, pp. 652-658
-
-
Navarro, V.1
Herrine, S.2
Katopes, C.3
-
5
-
-
30444443316
-
The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation
-
Sieders E, Hepkema BG, Peeters PM, et al. The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation. Liver Transpl 2005;11:1541-9.
-
(2005)
Liver Transpl
, vol.11
, pp. 1541-1549
-
-
Sieders, E.1
Hepkema, B.G.2
Peeters, P.M.3
-
6
-
-
0001315607
-
Successful sequential liver-kidney transplantation in patients with performed lymphocytotoxic antibodies
-
Fung JJ, Makowka L, Griffin M, et al. Successful sequential liver-kidney transplantation in patients with performed lymphocytotoxic antibodies. Clin Transplant 1987;1:187-94.
-
(1987)
Clin Transplant
, vol.1
, pp. 187-194
-
-
Fung, J.J.1
Makowka, L.2
Griffin, M.3
-
7
-
-
0014661390
-
Induction of immunological tolerance by porcine liver allografts
-
Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-6.
-
(1969)
Nature
, vol.223
, pp. 472-476
-
-
Calne, R.Y.1
Sells, R.A.2
Pena, J.R.3
-
8
-
-
33846928735
-
Operational tolerance in clinical liver transplantation: Emerging developments
-
Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl Immunol 2007;17:108-13.
-
(2007)
Transpl Immunol
, vol.17
, pp. 108-113
-
-
Tisone, G.1
Orlando, G.2
Angelico, M.3
-
9
-
-
0005984244
-
Actively acquired tolerance of foreign cells
-
Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603-6.
-
(1953)
Nature
, vol.172
, pp. 603-606
-
-
Billingham, R.E.1
Brent, L.2
Medawar, P.B.3
-
10
-
-
38549134052
-
Tolerance and chimerism after renal and hematopoietic-cell transplantation
-
Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008;358:362-8.
-
(2008)
N Engl J Med
, vol.358
, pp. 362-368
-
-
Scandling, J.D.1
Busque, S.2
Dejbakhsh-Jones, S.3
-
11
-
-
38549155221
-
Chimerism and tolerance in a recipient of a deceased-donor liver transplant
-
Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008;358:369-74.
-
(2008)
N Engl J Med
, vol.358
, pp. 369-374
-
-
Alexander, S.I.1
Smith, N.2
Hu, M.3
-
12
-
-
38549088096
-
HLA-mismatched renal transplantation without maintenance immunosuppression
-
Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-61.
-
(2008)
N Engl J Med
, vol.358
, pp. 353-361
-
-
Kawai, T.1
Cosimi, A.B.2
Spitzer, T.R.3
-
13
-
-
3843066657
-
Natural history of hepatitis C following liver transplantation
-
Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004;17:363-71.
-
(2004)
Curr Opin Infect Dis
, vol.17
, pp. 363-371
-
-
Rodriguez-Luna, H.1
Douglas, D.D.2
-
14
-
-
33845489455
-
Recurrence of autoimmune liver disease after liver transplantation: A systematic review
-
Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24.
-
(2006)
Liver Transpl
, vol.12
, pp. 1813-1824
-
-
Gautam, M.1
Cheruvattath, R.2
Balan, V.3
-
15
-
-
40649112628
-
Therapeutic management of posttransplant diabetes mellitus
-
Mannon RB. Therapeutic management of posttransplant diabetes mellitus. Transplant Rev 2008;22:116-24.
-
(2008)
Transplant Rev
, vol.22
, pp. 116-124
-
-
Mannon, R.B.1
-
16
-
-
55049119653
-
Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience
-
Xu X, Ling Q, He ZL, et al. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int 2008;7:465-70.
-
(2008)
Hepatobiliary Pancreat Dis Int
, vol.7
, pp. 465-470
-
-
Xu, X.1
Ling, Q.2
He, Z.L.3
-
17
-
-
0017157814
-
Biological effects of cyclosporin A: A new antilymphocytic agent
-
Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468-75.
-
(1976)
Agents Actions
, vol.6
, pp. 468-475
-
-
Borel, J.F.1
Feurer, C.2
Gubler, H.U.3
-
18
-
-
0018186018
-
Cyclosporin A in patients receiving renal allografts from cadaver donors
-
Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323-7.
-
(1978)
Lancet
, vol.2
, pp. 1323-1327
-
-
Calne, R.Y.1
White, D.J.2
Thiru, S.3
-
19
-
-
0003084993
-
The mode of action of Prograf (tacrolimus) and its significance for long-term graft survival
-
Hutchinson IV. The mode of action of Prograf (tacrolimus) and its significance for long-term graft survival. New Horizons Kidney Transplantation 1997 1997;1:22-6.
-
(1997)
New Horizons Kidney Transplantation
, vol.1997
, Issue.1
, pp. 22-26
-
-
Hutchinson, I.V.1
-
21
-
-
0042360213
-
Chronic renal failure after transplantation of a nonrenal organ
-
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
-
(2003)
N Engl J Med
, vol.349
, pp. 931-940
-
-
Ojo, A.O.1
Held, P.J.2
Port, F.K.3
-
22
-
-
34548812349
-
Therapeutic monitoring of calcineurin inhibitors for the nephrologist
-
Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374-84.
-
(2007)
Clin J Am Soc Nephrol
, vol.2
, pp. 374-384
-
-
Schiff, J.1
Cole, E.2
Cantarovich, M.3
-
23
-
-
33645106470
-
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
-
Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-7.
-
(2006)
Liver Transpl
, vol.12
, pp. 51-57
-
-
Firpi, R.J.1
Zhu, H.2
Morelli, G.3
-
24
-
-
33750713365
-
Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha
-
Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-62.
-
(2006)
Gastroenterology
, vol.131
, pp. 1452-1462
-
-
Henry, S.D.1
Metselaar, H.J.2
Lonsdale, R.C.3
-
25
-
-
0142182744
-
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes
-
Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8.
-
(2003)
Hepatology
, vol.38
, pp. 1282-1288
-
-
Watashi, K.1
Hijikata, M.2
Hosaka, M.3
-
26
-
-
33846238124
-
Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: Results of a meta-analysis
-
Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-9.
-
(2007)
Liver Transpl
, vol.13
, pp. 21-29
-
-
Berenguer, M.1
Royuela, A.2
Zamora, J.3
-
27
-
-
0033545299
-
Cyclosporine induces cancer progression by a cell-autonomous mechanism
-
Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
-
(1999)
Nature
, vol.397
, pp. 530-534
-
-
Hojo, M.1
Morimoto, T.2
Maluccio, M.3
-
28
-
-
0036174289
-
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor
-
Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
-
(2002)
Nat Med
, vol.8
, pp. 128-135
-
-
Guba, M.1
von Breitenbuch, P.2
Steinbauer, M.3
-
29
-
-
2442668989
-
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
-
Koehl G, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004;77:1319-26.
-
(2004)
Transplantation
, vol.77
, pp. 1319-1326
-
-
Koehl, G.1
Andrassy, J.2
Guba, M.3
-
30
-
-
0003188476
-
Sperimentate su culture pure di bacilli del carbonchio demonstrarano notevole potere antisettica.
-
Gosio B. Sperimentate su culture pure di bacilli del carbonchio demonstrarano notevole potere antisettica. C R Acad Med Torino 1893;61:484.
-
(1893)
C R Acad Med Torino
, vol.61
, pp. 484
-
-
Gosio, B.1
-
31
-
-
0014546166
-
The inhibition of nucleic acid synthesis by mycophenolic acid
-
Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
-
(1969)
Biochem J
, vol.113
, pp. 515-524
-
-
Franklin, T.J.1
Cook, J.M.2
-
32
-
-
0029115531
-
-
Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225- 32.
-
Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225- 32.
-
-
-
-
33
-
-
0034093785
-
Intravenous mycophenolate mofetil: Safety, tolerability, and pharmacokinetics
-
Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000;14:179-88.
-
(2000)
Clin Transplant
, vol.14
, pp. 179-188
-
-
Pescovitz, M.D.1
Conti, D.2
Dunn, J.3
-
34
-
-
34249075713
-
MMF to EC-MPS conversion: What makes the difference?
-
Schmidt H, Brockmann J. MMF to EC-MPS conversion: what makes the difference? Liver Transpl 2007;13:773-4.
-
(2007)
Liver Transpl
, vol.13
, pp. 773-774
-
-
Schmidt, H.1
Brockmann, J.2
-
35
-
-
0035941732
-
Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study
-
Schlitt HJ, Barkmann A, Böker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-91.
-
(2001)
Lancet
, vol.357
, pp. 587-591
-
-
Schlitt, H.J.1
Barkmann, A.2
Böker, K.H.W.3
-
36
-
-
0035941756
-
Mycophenolate mofetil monotherapy in liver transplantation
-
Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357:609- 10.
-
(2001)
Lancet
, vol.357
, pp. 609-610
-
-
Stewart, S.F.1
Hudson, M.2
Talbot, D.3
-
37
-
-
0032573724
-
A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation
-
Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998;66:1616-21.
-
(1998)
Transplantation
, vol.66
, pp. 1616-1621
-
-
Fisher, R.A.1
Ham, J.M.2
Marcos, A.3
-
38
-
-
0034657919
-
Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil
-
Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000;69:1886-90.
-
(2000)
Transplantation
, vol.69
, pp. 1886-1890
-
-
Barkmann, A.1
Nashan, B.2
Schmidt, H.H.3
-
39
-
-
49649087943
-
Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: Prediction of occurrence of leukopenia
-
Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl 2008;14:1165-73.
-
(2008)
Liver Transpl
, vol.14
, pp. 1165-1173
-
-
Hao, C.1
Anwei, M.2
Bing, C.3
-
40
-
-
37549061407
-
Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients
-
Hao C, Erzheng C, Anwei M, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007;13:1684-93.
-
(2007)
Liver Transpl
, vol.13
, pp. 1684-1693
-
-
Hao, C.1
Erzheng, C.2
Anwei, M.3
-
41
-
-
1442311438
-
Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus
-
Stangl JR, Carroll KL, Illichmann M, et al. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004;77:562-7.
-
(2004)
Transplantation
, vol.77
, pp. 562-567
-
-
Stangl, J.R.1
Carroll, K.L.2
Illichmann, M.3
-
42
-
-
34548709168
-
Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation
-
Nebbia G, Mattes FM, Sabin CA, et al. Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation. Transplantation 2007;84:605-10.
-
(2007)
Transplantation
, vol.84
, pp. 605-610
-
-
Nebbia, G.1
Mattes, F.M.2
Sabin, C.A.3
-
43
-
-
3042771789
-
A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection
-
Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004;10:52-7.
-
(2004)
Liver Transpl
, vol.10
, pp. 52-57
-
-
Zekry, A.1
Gleeson, M.2
Guney, S.3
-
44
-
-
0038299000
-
Sirolimus: Its discovery, biological properties, and mechanism of action
-
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S.
-
(2003)
Transplant Proc
, vol.35
-
-
Sehgal, S.N.1
-
45
-
-
0142155129
-
Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus
-
Fairbanks KD, Eustace JA, Fine D, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transplantation 2003;9:1079-85.
-
(2003)
Liver Transplantation
, vol.9
, pp. 1079-1085
-
-
Fairbanks, K.D.1
Eustace, J.A.2
Fine, D.3
-
46
-
-
34547851713
-
Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols
-
Diekmann F, Gutierrez-Dalmau A, Lopez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transpl 2007;22:2316-21.
-
(2007)
Nephrol Dial Transpl
, vol.22
, pp. 2316-2321
-
-
Diekmann, F.1
Gutierrez-Dalmau, A.2
Lopez, S.3
-
47
-
-
27644439969
-
Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus
-
Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23.
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 2517-2523
-
-
Bumbea, V.1
Kamar, N.2
Ribes, D.3
-
48
-
-
28544442713
-
Proteinuria following a switch from calcineurin inhibitors to sirolimus
-
Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-203.
-
(2005)
Transplantation
, vol.80
, pp. 1198-1203
-
-
Letavernier, E.1
Pe'raldi, M.N.2
Pariente, A.3
-
49
-
-
6444233347
-
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma
-
Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation 2004;10:1301-11.
-
(2004)
Liver Transplantation
, vol.10
, pp. 1301-1311
-
-
Kneteman, N.M.1
Oberholzer, J.2
Al Saghier, M.3
-
50
-
-
0037686693
-
Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications
-
Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003;9:463-8.
-
(2003)
Liver Transpl
, vol.9
, pp. 463-468
-
-
Dunkelberg, J.C.1
Trotter, J.F.2
Wachs, M.3
-
51
-
-
0344613988
-
Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
-
Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999;5:1298- 302.
-
(1999)
Nat Med
, vol.5
, pp. 1298-1302
-
-
Li, Y.1
Li, X.C.2
Zheng, X.X.3
-
52
-
-
0345164351
-
Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment
-
Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998;66:1387-8.
-
(1998)
Transplantation
, vol.66
, pp. 1387-1388
-
-
Li, Y.1
Zheng, X.X.2
Li, X.C.3
-
54
-
-
45549098562
-
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
-
Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008;105:7797-802.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 7797-7802
-
-
Sauer, S.1
Bruno, L.2
Hertweck, A.3
-
57
-
-
0037182139
-
Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy
-
Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
-
(2002)
Transplantation
, vol.73
, pp. 1565-1572
-
-
Luan, F.L.1
Hojo, M.2
Maluccio, M.3
-
58
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
-
(2007)
Cancer Cell
, vol.12
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
59
-
-
36048963331
-
Activation of the PTEN/ mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
-
Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/ mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007;104: 16158-63.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 16158-16163
-
-
Zhou, J.1
Wulfkuhle, J.2
Zhang, H.3
-
60
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
61
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
62
-
-
34248327483
-
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: Long-term outcomes and side effects
-
Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83:1162-8.
-
(2007)
Transplantation
, vol.83
, pp. 1162-1168
-
-
Toso, C.1
Meeberg, G.A.2
Bigam, D.L.3
-
63
-
-
33750433893
-
Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis
-
Neef M, Ledermann M, Saegesser H, et al. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006;45:786-96.
-
(2006)
J Hepatol
, vol.45
, pp. 786-796
-
-
Neef, M.1
Ledermann, M.2
Saegesser, H.3
-
64
-
-
35748950134
-
Impact of steroids on hepatitis C virus replication in vivo and in vitro
-
Henry SD, Metselaar HJ, Van Dijck J, et al. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007;1110:439-47.
-
(2007)
Ann N Y Acad Sci
, vol.1110
, pp. 439-447
-
-
Henry, S.D.1
Metselaar, H.J.2
Van Dijck, J.3
-
65
-
-
35748938770
-
Influence of steroids on HCV recurrence after liver transplantation: A prospective study
-
Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007;47:793-8.
-
(2007)
J Hepatol
, vol.47
, pp. 793-798
-
-
Vivarelli, M.1
Burra, P.2
La Barba, G.3
-
66
-
-
42149168448
-
Steroid avoidance in liver transplantation: Meta-analysis and meta-regression of randomized trials
-
Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14:512-25.
-
(2008)
Liver Transpl
, vol.14
, pp. 512-525
-
-
Segev, D.L.1
Sozio, S.M.2
Shin, E.J.3
-
67
-
-
34547588360
-
Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation
-
Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007;13:1039- 44.
-
(2007)
Liver Transpl
, vol.13
, pp. 1039-1044
-
-
Soliman, T.1
Hetz, H.2
Burghuber, C.3
-
68
-
-
34249083437
-
Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: Case report and literature review
-
Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007;13:647-50.
-
(2007)
Liver Transpl
, vol.13
, pp. 647-650
-
-
Lundquist, A.L.1
Chari, R.S.2
Wood, J.H.3
-
71
-
-
35748953121
-
Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: Clinical efficacy and potential mechanisms of action
-
Lytton SD, Denton CP, Nutzenberger AM. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action. Ann N Y Acad Sci 2007;1110:285-96.
-
(2007)
Ann N Y Acad Sci
, vol.1110
, pp. 285-296
-
-
Lytton, S.D.1
Denton, C.P.2
Nutzenberger, A.M.3
-
72
-
-
0036192366
-
Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial
-
Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-42.
-
(2002)
Liver Transpl
, vol.8
, pp. 132-142
-
-
Neuhaus, P.1
Clavien, P.A.2
Kittur, D.3
-
73
-
-
2942726371
-
Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage
-
Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004;10:728-33.
-
(2004)
Liver Transpl
, vol.10
, pp. 728-733
-
-
Liu, C.L.1
Fan, S.T.2
Lo, C.M.3
-
74
-
-
33847678151
-
Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months
-
Ramirez CB, Doria C, Di Francesco F, et al. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007;138:198-204.
-
(2007)
J Surg Res
, vol.138
, pp. 198-204
-
-
Ramirez, C.B.1
Doria, C.2
Di Francesco, F.3
-
75
-
-
0034719368
-
Experience with daclizumab in liver transplantation: Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation
-
Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000;69:307-11.
-
(2000)
Transplantation
, vol.69
, pp. 307-311
-
-
Hirose, R.1
Roberts, J.P.2
Quan, D.3
-
76
-
-
0036193103
-
Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients
-
Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-31.
-
(2002)
Liver Transpl
, vol.8
, pp. 123-131
-
-
Calmus, Y.1
Scheele, J.R.2
Gonzalez-Pinto, I.3
-
77
-
-
34248146578
-
+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation
-
+ regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007;178:6066-72.
-
(2007)
J Immunol
, vol.178
, pp. 6066-6072
-
-
Demirkiran, A.1
Bosma, B.M.2
Kok, A.3
-
79
-
-
33845406639
-
Anti-CD25 mAB administration prevents spontaneous liver transplant tolerance
-
Li W, Carper K, Liang Y, et al. Anti-CD25 mAB administration prevents spontaneous liver transplant tolerance. Transplant Proc 2006;38:3207-8.
-
(2006)
Transplant Proc
, vol.38
, pp. 3207-3208
-
-
Li, W.1
Carper, K.2
Liang, Y.3
-
80
-
-
0021227678
-
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
-
Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;2:483-6.
-
(1984)
Lancet
, vol.2
, pp. 483-486
-
-
Waldmann, H.1
Polliak, A.2
Hale, G.3
-
81
-
-
33746921599
-
The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation
-
Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006;19:705-14.
-
(2006)
Transpl Int
, vol.19
, pp. 705-714
-
-
Magliocca, J.F.1
Knechtle, S.J.2
-
82
-
-
20544458513
-
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years
-
Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005;5:1347-53.
-
(2005)
Am J Transplant
, vol.5
, pp. 1347-1353
-
-
Watson, C.J.1
Bradley, J.A.2
Friend, P.J.3
-
83
-
-
47249132479
-
Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells
-
Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008;8:1529-36.
-
(2008)
Am J Transplant
, vol.8
, pp. 1529-1536
-
-
Pascual, J.1
Bloom, D.2
Torrealba, J.3
-
84
-
-
33749444584
-
Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation
-
Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19:885-92.
-
(2006)
Transpl Int
, vol.19
, pp. 885-892
-
-
Barth, R.N.1
Janus, C.A.2
Lillesand, C.A.3
-
85
-
-
40449101381
-
+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H
-
+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802.
-
(2008)
Am J Transplant
, vol.8
, pp. 793-802
-
-
Bloom, D.D.1
Chang, Z.2
Fechner, J.H.3
-
86
-
-
2342582720
-
Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation
-
Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004;77:1209-14.
-
(2004)
Transplantation
, vol.77
, pp. 1209-1214
-
-
Tzakis, A.G.1
Tryphonopoulos, P.2
Kato, T.3
-
87
-
-
6344256213
-
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: With particular reference to hepatitis C virus
-
Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-71.
-
(2004)
Transplantation
, vol.78
, pp. 966-971
-
-
Marcos, A.1
Eghtesad, B.2
Fung, J.J.3
-
88
-
-
61649095158
-
Six year experience with Campath-1H (C1H) induction in adult liver transplantation
-
Tryphonopoulos P, Weppler D, Nishida S, et al. Six year experience with Campath-1H (C1H) induction in adult liver transplantation. Am J Transplant 2008;8(suppl 2):307.
-
(2008)
Am J Transplant
, vol.8
, Issue.SUPPL. 2
, pp. 307
-
-
Tryphonopoulos, P.1
Weppler, D.2
Nishida, S.3
-
89
-
-
23944502334
-
Costimulation blockade with belatacept in renal transplantation
-
Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. New EnglJ Med 2005;353:770-81.
-
(2005)
New EnglJ Med
, vol.353
, pp. 770-781
-
-
Vincenti, F.1
Larsen, C.2
Durrbach, A.3
-
91
-
-
9144272645
-
Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection
-
Metzler B, Gfeller P, Bigaud M, et al. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection. J Immunol 2004;173:7025-36.
-
(2004)
J Immunol
, vol.173
, pp. 7025-7036
-
-
Metzler, B.1
Gfeller, P.2
Bigaud, M.3
-
92
-
-
12744274512
-
Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB
-
Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes 2005;54:443-51.
-
(2005)
Diabetes
, vol.54
, pp. 443-451
-
-
Rayat, G.R.1
Gill, R.G.2
-
93
-
-
34250202520
-
A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation
-
Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7:1770- 7.
-
(2007)
Am J Transplant
, vol.7
, pp. 1770-1777
-
-
Vincenti, F.1
Mendez, R.2
Pescovitz, M.3
-
94
-
-
33745063675
-
Regulatory dendritic cell therapy in organ transplantation
-
McCurry KR, Colvin BL, Zahorchak AF, et al. Regulatory dendritic cell therapy in organ transplantation. Transpl Int 2006;19:525-38.
-
(2006)
Transpl Int
, vol.19
, pp. 525-538
-
-
McCurry, K.R.1
Colvin, B.L.2
Zahorchak, A.F.3
-
95
-
-
40449104477
-
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice
-
Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008;180:335-49.
-
(2008)
J Immunol
, vol.180
, pp. 335-349
-
-
Brem-Exner, B.G.1
Sattler, C.2
Hutchinson, J.A.3
-
96
-
-
33845491455
-
Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion
-
Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006;108:4260-7.
-
(2006)
Blood
, vol.108
, pp. 4260-4267
-
-
Hoffmann, P.1
Eder, R.2
Boeld, T.J.3
-
97
-
-
53549133080
-
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation
-
Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008;21:728-41.
-
(2008)
Transpl Int
, vol.21
, pp. 728-741
-
-
Hutchinson, J.A.1
Riquelme, P.2
Brem-Exner, B.G.3
-
98
-
-
53549101269
-
A cell-based approach to the minimization of immunosuppression in renal transplantation
-
Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008;21:742-54.
-
(2008)
Transpl Int
, vol.21
, pp. 742-754
-
-
Hutchinson, J.A.1
Brem-Exner, B.G.2
Riquelme, P.3
-
99
-
-
58149204330
-
Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells
-
Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008;21:808-13.
-
(2008)
Transpl Int
, vol.21
, pp. 808-813
-
-
Hutchinson, J.A.1
Roelen, D.2
Riquelme, P.3
-
100
-
-
0030899508
-
Weaning of immunosuppression in liver transplant recipients
-
Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63:243-9.
-
(1997)
Transplantation
, vol.63
, pp. 243-249
-
-
Mazariegos, G.V.1
Reyes, J.2
Marino, I.R.3
-
101
-
-
20344366308
-
Long-term outcome of immunosuppression withdrawal after liver transplantation
-
Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005;37:1708-9.
-
(2005)
Transplant Proc
, vol.37
, pp. 1708-1709
-
-
Girlanda, R.1
Rela, M.2
Williams, R.3
-
102
-
-
0035881424
-
Weaning of immunosuppression in living donor liver transplant recipients
-
Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72:449-54.
-
(2001)
Transplantation
, vol.72
, pp. 449-454
-
-
Takatsuki, M.1
Uemoto, S.2
Inomata, Y.3
-
103
-
-
10044262162
-
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation
-
Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004;4:2118-25.
-
(2004)
Am J Transplant
, vol.4
, pp. 2118-2125
-
-
Li, Y.1
Koshiba, T.2
Yoshizawa, A.3
-
105
-
-
48749084927
-
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients
-
Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008;118:2845-57.
-
(2008)
J Clin Invest
, vol.118
, pp. 2845-2857
-
-
Martinez-Llordella, M.1
Lozano, J.J.2
Puig-Pey, I.3
|